



Contact:

David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

**MILESTONE SCIENTIFIC TO PRESENT AT
1st GLOBAL LIFE SCIENCES CONFERENCE IN WARSAW**

LIVINGSTON, NJ – July 17, 2013 – Milestone Scientific Inc. (OTCQB: MLSS), a leading medical research and development company that designs and patents innovative injection technology, today announced that Leonard Osser, Chief Executive Officer, Joseph D’Agostino, Chief Financial Officer & Chief Operating Officer, and Mark Hochman, D.D.S., Director of Clinical Affairs, will present at the upcoming 1st Global Life Sciences Conference in Warsaw on September 16-17, 2013 at the trading floor of the Warsaw Stock Exchange, Warsaw, Poland. A recording of the presentation will be posted on Milestone’s website following the conference.

Warsaw, the financial capital of Central and Eastern Europe, is a major center of life science investment. On September 16-17, at the Global Life Sciences Conference, over 100 leading life science institutional investors, fund managers and analysts from Central and Eastern Europe will gather in Warsaw to discuss and assess new investment opportunities. They will have access there to Milestone’s management and scientific team through a corporate presentation and small group meetings.

The organizers of this event are: WDM Capital, Wedbush Securities Europe and the Warsaw Stock Exchange. For more information please visit: <http://lscwarsaw.com>

About Milestone Scientific Inc.

Milestone Scientific Inc. (OTCQB: MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone’s groundbreaking computer-controlled systems make injections more precise, more efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

SafeHarbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2012. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.